

10/509773

Express Mail No. EV577672692HS

14 APR 2005

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	SMAR-044
	First Named Inventor	DELANEY, ALLEN D.
	Application Number	10/509,773
	Confirmation No.	3141
	International Filing Date	March 19, 2003
	Group Art Unit	
	Examiner Name	
	Title:	"CANCER ASSOCIATED PROTEIN PHOSPHATASES AND THEIR USES"

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. SMAR-044 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: April 14, 2005

By: 
Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/509,773

International Filing Date March 19, 2003

First Named Inventor DELANEY, Allen D.

Art Unit

Examiner Name

Attorney Docket Number SMAR-044

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	US	--			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	01/12819	A2	02-22-2001	Sugen, Inc.	Page 107, lines 24- page 110, line 15, claims 1-23 and Figure 3	
	B2	WO	01/02581	A1	01-11-2001	Ceptyr, Inc.	SEQ ID NO: 2	
	B3	WO	01/02582	A1	01-11-2001	Ceptyr, Inc.	SEQ ID NO:2, Example 2, page 2, line 17 to page 8, page 43, lines 7, claims 1-98	
	B4	WO	01/81590	A2	11-01-2001	Incyte Genomics, Inc.	SEQ ID NO: 10	
	B5	WO	98/14596	A2	10-03-1996	Incyte Pharmaceuticals, Inc.		
	B6	WO	00/12525	A1	03-09-2000	Quark Biotech, Inc.	SEQ ID NO: 8	
	B7	WO	01/72295	A2	10-04-2001	Corixa Corporation		
	B8	EP	1033401	A2	09-06-2000	Genset (FR)	SEQ ID NO: 12433	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/509,773
International Filing Date	March 19, 2003
First Named Inventor	DELANEY, Allen D.
Art Unit	
Examiner Name	
Attorney Docket Number	SMAR-044

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ADACHI, M. et al., "Protein-tyrosine phosphatase expression in pre-B cell NALM-6" Cancer Res (1992) 52(3):737-740.	
	C2	ALONSO, A. et al., "Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHS), a new dual specificity phosphatase related to VHS related (VHR)" J Biol Chem (2002) 277(7):5524-5528.	
	C3	CROSS, T.G. et al., "Serine/threonine protein kinases and apoptosis" Exp Cell Res (2000) 256(1):34-41.	
	C4	Genbank Accession No. AL050040, Submitted by Ansoorge, W., Wirkner, U., Mewes, H.W., et al. Direct submission May 15, 1999, partial CDS, clone from human, publication date July 4, 2000.	
	C5	Genbank Accession No. NP060232, Hypothetical protein. Authors Kawakami, T., Noguchi, S., Itoh, T., et al. NEDO human cDNA sequencing project, unpublished.	
	C6	IRVINE, R.F. et al., "Inositol lipids in cell signalling" Curr Opin Cell Bio (1992) 4(2):212-219.	
	C7	NANDURKAR, H.H., et al. "Characterization of an adapter subunit to a phosphatidylinositol (3)P 3-phosphatase: identification of a myotubularin-related protein lacking catalytic activity" Proc Natl Acad Sci USA (2001) 98(17):9499-9504.	
	C8	NOMURA, N. et al., Prediction of the coding sequences of unidentified human genes. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1" DNA Res (1994) 1(1):27-35.	
	C9	OHSUGI, M. et al., "Molecular cloning and characterization of a novel cytoplasmic protein-tyrosine phosphatase that is specifically expressed in spermatocytes" J Biol Chem (1997) 272(52):33092-33099.	
	C10	PENG, Y. et al., "The gene encoding human nuclear protein tyrosine phosphatase PRL-1. Cloning, chromosomal localization, and identification of an intron enhancer" J Biol Chem (1998) 273(27):17286-17295.	
	C11	SCHULTZ, J. et al., "More than 1,000 putative new human signalling proteins revealed by EST data mining" Nature Genetics (2000) 25(2):201-4.	
	C12	SHEN, Y. et al., "Activation of the JNK signaling pathway by a dual-specificity phosphatase, JSP-1" PNAS USA (2001) 98(24):13613-13618.	
	C13	SU, A.I., et al. "Molecular classification of human carcinomas by use of gene expression signatures" Cancer Res (2001) 61(20):7388-7393.	
	C14	ZANKE, B. et al., "Cloning and expression of an inducible lymphoid-specific protein tyrosine phosphatase (HePTPase)" Eur J Immunol (1992) 22(1):235-239.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.